ES2987802T3 - Uso de comprimidos bucodispersables de riluzol para el tratamiento de enfermedades - Google Patents

Uso de comprimidos bucodispersables de riluzol para el tratamiento de enfermedades Download PDF

Info

Publication number
ES2987802T3
ES2987802T3 ES19849456T ES19849456T ES2987802T3 ES 2987802 T3 ES2987802 T3 ES 2987802T3 ES 19849456 T ES19849456 T ES 19849456T ES 19849456 T ES19849456 T ES 19849456T ES 2987802 T3 ES2987802 T3 ES 2987802T3
Authority
ES
Spain
Prior art keywords
riluzole
pharmaceutical composition
use according
cancer
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES19849456T
Other languages
English (en)
Spanish (es)
Inventor
Vladimir Coric
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biohaven Therapeutics Ltd
Original Assignee
Biohaven Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biohaven Therapeutics Ltd filed Critical Biohaven Therapeutics Ltd
Application granted granted Critical
Publication of ES2987802T3 publication Critical patent/ES2987802T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2063—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
ES19849456T 2018-08-16 2019-08-15 Uso de comprimidos bucodispersables de riluzol para el tratamiento de enfermedades Active ES2987802T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862764864P 2018-08-16 2018-08-16
PCT/US2019/046709 WO2020037152A1 (en) 2018-08-16 2019-08-15 Use of riluzole oral disintigrating tablets for treating diseases

Publications (1)

Publication Number Publication Date
ES2987802T3 true ES2987802T3 (es) 2024-11-18

Family

ID=69525906

Family Applications (1)

Application Number Title Priority Date Filing Date
ES19849456T Active ES2987802T3 (es) 2018-08-16 2019-08-15 Uso de comprimidos bucodispersables de riluzol para el tratamiento de enfermedades

Country Status (14)

Country Link
US (1) US20210315865A1 (cg-RX-API-DMAC7.html)
EP (1) EP3836922B1 (cg-RX-API-DMAC7.html)
JP (2) JP2021534160A (cg-RX-API-DMAC7.html)
KR (1) KR20210045423A (cg-RX-API-DMAC7.html)
CN (1) CN112584831A (cg-RX-API-DMAC7.html)
AU (1) AU2019322889A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021002692A2 (cg-RX-API-DMAC7.html)
EA (1) EA202190544A1 (cg-RX-API-DMAC7.html)
ES (1) ES2987802T3 (cg-RX-API-DMAC7.html)
IL (1) IL280657A (cg-RX-API-DMAC7.html)
MX (2) MX2021001563A (cg-RX-API-DMAC7.html)
PH (1) PH12021550218A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202100880VA (cg-RX-API-DMAC7.html)
WO (1) WO2020037152A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL299301A (en) * 2020-06-24 2023-02-01 Biohaven Therapeutics Ltd Compositions and methods for the treatment of obsessive compulsive disorder
EP4240308A4 (en) * 2020-10-05 2024-10-30 Icahn School of Medicine at Mount Sinai Riluzole for the treatment of alzheimer's disease
LT4243797T (lt) 2020-11-16 2026-06-10 Orcosa Inc. Greitos infuzijos platforma ir kompozicijos, skirtos žmonių terapiniam gydymui
US11672761B2 (en) 2020-11-16 2023-06-13 Orcosa Inc. Rapidly infusing platform and compositions for therapeutic treatment in humans
CN114177153B (zh) * 2021-12-20 2023-04-07 平顶山市第二人民医院 一种利鲁唑口崩片及其制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1548022A (en) 1976-10-06 1979-07-04 Wyeth John & Brother Ltd Pharmaceutial dosage forms
GB9908014D0 (en) 1999-04-08 1999-06-02 Scherer Corp R P Pharmaceutical compositions
WO2004047793A1 (en) * 2002-11-26 2004-06-10 Alk-Abelló A/S Pharmaceutical allergen product
US9241902B2 (en) * 2003-12-17 2016-01-26 R.P. Scherer Technologies, Llc Chewable soft capsules containing ungelatinized starch
ES2819303T3 (es) * 2005-04-05 2021-04-15 Univ Yale Agentes moduladores del glutamato en el tratamiento de trastornos mentales
US20080260823A1 (en) * 2007-04-20 2008-10-23 Sciele Pharma, Inc. Orally disintegrating tablet comprising glycopyrrolate for treating sialorrhea
WO2011019375A1 (en) * 2009-08-10 2011-02-17 Teva Pharmaceutical Industries Ltd. Treatment of bdnf-related disorders using laquinimod
US9041556B2 (en) 2011-10-20 2015-05-26 Apple Inc. Method for locating a vehicle
US9434704B2 (en) * 2012-05-08 2016-09-06 Cellix Bio Private Limited Compositions and methods for the treatment of neurological degenerative disorders
RS59490B1 (sr) * 2014-11-21 2019-12-31 Biohaven Therapeutics Ltd Sublingvalna formulacija riluzola
CA2967659A1 (en) * 2014-11-21 2016-05-26 Biohaven Pharmaceutical Holding Company Ltd. Sublingual administration of riluzole
US10258611B2 (en) * 2014-11-26 2019-04-16 Medicinova, Inc. Combination of ibudilast and riluzole and methods of using same
DK3265448T3 (da) * 2015-03-03 2022-03-28 Biohaven Therapeutics Ltd Riluzol-prodrugs og anvendelse deraf
MX2019009038A (es) * 2017-01-31 2019-12-09 L Manfredi Paolo D-metadona y sus derivados para uso en el tratamiento de trastornos del sistema nervioso.

Also Published As

Publication number Publication date
MX2024007642A (es) 2024-07-04
EP3836922A4 (en) 2022-05-04
JP2024010017A (ja) 2024-01-23
SG11202100880VA (en) 2021-02-25
WO2020037152A1 (en) 2020-02-20
AU2019322889A1 (en) 2021-03-04
PH12021550218A1 (en) 2021-12-06
EP3836922B1 (en) 2024-08-07
IL280657A (en) 2021-03-25
US20210315865A1 (en) 2021-10-14
EP3836922A1 (en) 2021-06-23
MX2021001563A (es) 2021-06-15
EA202190544A1 (ru) 2021-06-18
EP3836922C0 (en) 2024-08-07
CA3109769A1 (en) 2020-02-20
JP2021534160A (ja) 2021-12-09
BR112021002692A2 (pt) 2021-05-11
CN112584831A (zh) 2021-03-30
KR20210045423A (ko) 2021-04-26

Similar Documents

Publication Publication Date Title
EP3836922B1 (en) Use of riluzole oral disintigrating tablets for treating diseases
ES2425114T3 (es) CDP-colina y uridina para el tratamiento del abuso del acohol
ES2733929T3 (es) Una combinación farmacéutica para el tratamiento del melanoma
US20260014123A1 (en) Use of riluzole oral disintegrating tablets for treating diseases
ES2996892T3 (en) Use of riluzole prodrugs to treat ataxias
ES3060532T3 (en) Sublingual formulation of riluzole
WO2008023362A2 (en) Use of a combination of methotrexate and an a3ar agonist for the treatment of cancer
JP5788527B2 (ja) キナーゼ阻害剤の副作用低減剤
IT201800004108A1 (it) Composizione a base naturale per l’uso nel trattamento dello stress cronico caratterizzato da disturbi dell’umore e/o ansia
ES2935705T3 (es) Un ligando del receptor GABA A
Kleindienst et al. Efect of dimethyl sulfoxide on blood—-brain barrier integrity following middle cerebral artery OC--clusion in the rat
ES2517367T3 (es) Procedimiento de tratamiento de cáncer pancreático
CA3109769C (en) Use of riluzole oral disintigrating tablets for treating diseases
EA046859B1 (ru) Применение распадающихся в полости рта таблеток рилузола для лечения заболеваний
ES2539160T3 (es) Procedimiento de tratamiento de cáncer gástrico
TW201934123A (zh) 預防或治療癌症之包含pi3激酶抑制劑與細胞毒性抗癌物的醫藥組成物
CN107243010A (zh) 血红素在改善睡眠障碍的药物及保健食品中的应用
ES2349535T3 (es) Método de tratamiento de un trastorno de ansiedad.
HK40033906A (en) Use of riluzole prodrugs to treat ataxias
HK40033906B (en) Use of riluzole prodrugs to treat ataxias
HK40037184A (en) Use of riluzole prodrugs to treat ataxias
JP2010222347A (ja) Pde5阻害剤及びカルニチンを含有する医薬組成物